217 related articles for article (PubMed ID: 9217972)
1. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme.
Hayashi Y; Ueki K; Waha A; Wiestler OD; Louis DN; von Deimling A
Brain Pathol; 1997 Jul; 7(3):871-5. PubMed ID: 9217972
[TBL] [Abstract][Full Text] [Related]
2. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
3. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
4. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
5. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Liberski PP
Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
[TBL] [Abstract][Full Text] [Related]
6. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
7. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of radiographically defined de novo glioblastoma multiforme.
Tortosa A; Ino Y; Odell N; Swilley S; Sasaki H; Louis DN; Henson JW
Neuropathol Appl Neurobiol; 2000 Dec; 26(6):544-52. PubMed ID: 11123721
[TBL] [Abstract][Full Text] [Related]
9. Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.
Rawnsley JD; Srivatsan ES; Chakrabarti R; Billings KR; Wang MB
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):863-7. PubMed ID: 9260553
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic analysis of giant cell glioblastomas.
Meyer-Puttlitz B; Hayashi Y; Waha A; Rollbrocker B; Boström J; Wiestler OD; Louis DN; Reifenberger G; von Deimling A
Am J Pathol; 1997 Sep; 151(3):853-7. PubMed ID: 9284834
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
[TBL] [Abstract][Full Text] [Related]
12. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
13. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.
Maelandsmo GM; Berner JM; Flørenes VA; Forus A; Hovig E; Fodstad O; Myklebost O
Br J Cancer; 1995 Aug; 72(2):393-8. PubMed ID: 7640224
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia.
Zhou M; Gu L; Yeager AM; Findley HW
Pediatr Hematol Oncol; 1997; 14(2):141-50. PubMed ID: 9089742
[TBL] [Abstract][Full Text] [Related]
15. Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells.
Jagasia AA; Sher DA; Le Moine PJ; Kim DH; Moldwin RL; Smith SD; Diaz MO
Leukemia; 1996 Apr; 10(4):624-8. PubMed ID: 8618438
[TBL] [Abstract][Full Text] [Related]
16. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.
Nakao M; Yokota S; Kaneko H; Seriu T; Koizumi S; Takaue Y; Fujimoto T; Misawa S
Leukemia; 1996 Feb; 10(2):249-54. PubMed ID: 8637233
[TBL] [Abstract][Full Text] [Related]
17. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE; Ichimura K; Reifenberger G; Collins VP
Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821
[TBL] [Abstract][Full Text] [Related]
18. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
Hegi ME; zur Hausen A; Rüedi D; Malin G; Kleihues P
Int J Cancer; 1997 Sep; 73(1):57-63. PubMed ID: 9334810
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
20. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]